Back to Authors

Dong, C.

Mayo Clinic

Takeda Development Center Americas, Inc. (TDCA), Lexington MA

Citations 1

S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
Ansell, S., Straus, David J. , Kim, W. S., Gallamini, Andrea , Ramchandren, Radhakrishnan , Friedberg, Jonathan W. , Eom, Hyeon‐Seok , Dong, C., Campana, Frank, Fenton, Keenan , Puhlmann, Markus , Hutchings, Martin , Connors, Joseph M. , Advani, Ranjana H. , Evens, Andrew M. , Smolewski, Piotr , Savage, Kerry J. , Bartlett, Nancy L. , Abramson, Jeremy S. , Radford, John

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 101-102

10.1097/01.hs9.0000843692.94815.d7 Get It